Risk factors

Editas Medicine (EDIT) risk factors

Item 1A of every Editas Medicine, Inc. 10-K on file, and what changed from one year to the next.

Open EDIT in Gloomberb →
  • FY2025 10-K risk factors

    64 risks, 6 new, 10 dropped, 15 reworded since the prior year. Editas Medicine highlights preclinical reliance on EDIT-401, ongoing net losses totaling $1.6 billion, and risks from U.S. government shutdowns impacting FDA reviews.

    Filed Mar 09, 2026
  • FY2024 10-K risk factors

    68 risks. Editas faces significant operating losses, an accumulated deficit of $1.47 billion, and requires substantial additional capital.

    Filed Mar 05, 2025